BioSpace News Archive

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of David Lubner, a senior finance executive with over 25 years of experience, to Vor’s Board of Directors. “David’s expertise as a life sciences leader with a deep understanding of strategy, finance, capital markets and operations will benefit us greatly moving for

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that Drew Fromkin, Chief Executive Officer, will present at the LifeSci Partners Private Healthcare Company Virtual Summer Symposium, occurring August 4-5, 2020. Mr. Fromkin will also participate in

Polarean Scientific Presentations on Hyperpolarized 129 Xenon at Upcoming Medical Meetings - Polarean’s investigational drug/device lung diagnostic to be prominently featured - Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences DURHAM, N.C.--( BUSINESS WIRE )-- Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnost

(“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of single-port robotic surgical technologies, announces that it has completed design enhancements to instruments compatible for use with its single-port robotic surgical system. As previously disclosed, the Company resumed development of instruments for its single-port robotic surgical system

Study conducted at 109 hospitals with oversight by 10 Japanese professional societies, including Japanese Circulation Society

The Froedtert & MCW health network and Network Health, a Wisconsin-based health insurer, today announced they are improving patients’ ability to manage diabetes by using digital health as part of the care team’s treatment approach.

Jia Xie, PhD, a prominent researcher at Scripps Research responsible for inventing a collection of new technologies for antibody drug discovery and cell therapy Alexey V. Stepanov, PhD, a leading research expert in developing personalized therapeutic tools for lymphoproliferative disease using cell therapy

Aytu BioScience today announced the approval of ZolpiMist® (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia.

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that, given the fluidity created by the COVID-19 pandemic and level of uncertainty at the time when Catalent last provided financial guidance on May 5, 2020, it is providing certain preliminary finan

XP-0863 Phase 1b results and regulatory feedback support direct to Phase 3 registration study in both pediatric and adult patients with epilepsy